Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Next Previous
X
Search
Trial Profile

Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Sep 2016 Status changed from active, no longer recruiting to discontinued due Slow accrual.
    • 29 Jul 2015 Planned End Date changed from 1 Oct 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 29 Jul 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top